Rankings
▼
Calendar
KNSA Q3 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q3 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$99M
+719.6% YoY
Gross Profit
$87M
87.4% margin
Operating Income
$46M
46.8% margin
Net Income
$224M
226.0% margin
EPS (Diluted)
$3.18
QoQ Revenue Growth
+267.5%
Cash Flow
Operating Cash Flow
$62M
Free Cash Flow
$62M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$460M
Total Liabilities
$76M
Stockholders' Equity
$384M
Cash & Equivalents
$176M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$99M
$12M
+719.6%
Gross Profit
$87M
$8M
+949.6%
Operating Income
$46M
-$31M
+251.3%
Net Income
$224M
-$31M
+833.7%
Revenue Segments
Product
$33M
100%
← FY 2022
All Quarters
Q4 2022 →